Clinical Trials Logo

Clinical Trial Summary

Tyrosine Kinase Inhibitors (TKIs) especially higher generation TKI have higher CNS penetration rates and have shown favorable response rates in brain metastases. Brain radiotherapy/surgery is the standard treatment in brain metastases especially symptomatic metastases, however, the role of local treatment especially in driver mutation-positive non-small cell lung cancer with asymptomatic brain metastases is being questioned given their potential side effects. No randomized trial has shown the superiority of early vs delayed cranial RT in asymptomatic BM of driver mutated NSCLC.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05236946
Study type Interventional
Source Tata Memorial Hospital
Contact Anil Tibdewal, MD
Phone 9122 2417 7000
Email aniltibdewal@gmail.com
Status Recruiting
Phase Phase 3
Start date November 10, 2020
Completion date July 2026